Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

Finally, let's turn to the New England Journal of Medicine. Speaking of closing the loop, this is the final analysis of overall survival with pembrolizumab in early-stage triple-negative breast cancer ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. In this phase 3 trial, we randomly ...